Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

ions.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus, or HPV. The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include clinical development and other projections as well as statements regarding the Company's future plans, objectives, performance, operating expenses, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: evaluation of the remaining cohort by the end of the second quarter; the beginning of our Phase 2 clinical program; and continued advancement of HspE7 for HPV-related diseases.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by su
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... BURNIE, Md. , Aug. 19, 2014 ... clinical research industry, recently announced the formation of the ... pleased to announce the addition of Dr. William ... Photo - http://photos.prnewswire.com/prnh/20140818/136957 The ... across a variety of therapeutic areas and set strategic ...
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/19/2014)... August 19, 2014 Sales Horizons, a ... its online sales skills training course to ... , MedTech clinical staff spend the majority of their ... standalone medical center, or physician practice – providing support ... why stop there? Sales Horizons believes clinical staff are ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... Kathleen A. Maguire-Zeiss, Brandon K. Harv e y, Rita E. Giuliano and,H ... , Introduction , ... number of factors, including , method ... transfection of mammalian cells has proven to yield ...
... Menu B. Leddy, Biotechnology Research Department,Orange County ... , Introduction ... of bacterial species from membrane , ... of bacterial cells from membrane biofilms cannot be ...
... , Introduction , ... use as primers , or probes in genetic ... traditionally been done by slab gel electrophoresis or HPLC, but these , ... not provide desired quantitative precision or automation. Capillary ...
Cached Biology Technology:Commercial Plasmid Preparation Methods Yield DNA With Different Transfection Capabilities 2Commercial Plasmid Preparation Methods Yield DNA With Different Transfection Capabilities 3Commercial Plasmid Preparation Methods Yield DNA With Different Transfection Capabilities 4Commercial Plasmid Preparation Methods Yield DNA With Different Transfection Capabilities 5Commercial Plasmid Preparation Methods Yield DNA With Different Transfection Capabilities 6Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 2Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 3Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 4Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 5Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 6Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 7Oligonucleotide Purity Analysis by Capillary Electrophoresis 2Oligonucleotide Purity Analysis by Capillary Electrophoresis 3
(Date:8/20/2014)... screening outcomes of approximately 3 million infants, a team ... the University of Massachusetts Medical School, have shown that ... successfully implemented across public health newborn screening programs. Data ... 20 issue of the Journal of the American ... of SCID in newborns is higher than previously thought ...
(Date:8/20/2014)... that acral melanomas the rare type of skin cancer ... distinct from other more common types of skin cancer, according ... Pigment Cell & Melanoma Research . , Acral melanoma ... the feet, nail-beds and other hairless parts of the skin. ... by UV damage from the sun. , The team, from ...
(Date:8/20/2014)... into a chili pepper causes a burning spiciness that ... exploring the chili pepper,s effect are using their findings ... of pain, which can be caused by inflammation or ... which is being tested in clinical trials, in ACS, ... and colleagues explain that decades ago, scientists had pegged ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... after the world,s first ultrasonic detection device invented ... Virginia Tech Carilion Research Institute scientists have ... have long suspected: ultrasound applied to the periphery, such ... to the brain. And that,s just the ...
... ship is at anchor for longer periods algae, shells and ... economic losses of billions of Dollar. Biological growth on the ... the hull below the waterline which has a braking effect ... basified bio layer, the consumption of fuel can increase by ...
... a simple "drag-and-drop" computer interface and DNA self-assembly ... drug development that could drastically reduce the time ... work supported by a National Science Foundation (NSF) ... NanoLabs of Reston, Va., recently developed and began ...
Cached Biology News:Neuroscientists prove ultrasound can be tweaked to stimulate different sensations 2Neuroscientists prove ultrasound can be tweaked to stimulate different sensations 3Keeping ship hulls free of marine organisms 2Drag-and-drop DNA 2Drag-and-drop DNA 3Drag-and-drop DNA 4
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Blimp-1 (H-150)...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
PSGL-1 (215)...
Biology Products: